CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells

被引：6

作者：

Pu, Yiyi ^{[1
,2
]}

Yan, Dongmei ^{[2
]}

Tu, Linglan ^{[2
]}

Cheng, Liyan ^{[2
]}

Yu, Jie ^{[2
]}

Li, Zhuduo ^{[2
]}

Zheng, Xiaoliang ^{[2
]}

Wang, Xinbao ^{[1
]}

机构：

[1] Canc Hosp Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Hepatobiliary Pancreat Surg, Hangzhou, Zhejiang, Peoples R China

[2] Hangzhou Med Coll, Sch Bioengn, Hangzhou, Zhejiang, Peoples R China

来源：

DISEASE MARKERS | 2022年 / 2022卷

关键词：

CANCER-CELLS; GENE; CHEMOSENSITIVITY; MECHANISMS; EXPRESSION; EFFICACY; 5-FU;

D O I：

10.1155/2022/6907057

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background. 5-Fluorouracil (5-FU) has been widely applied in treating cancers. However, its usage is largely limited in hepatocellular carcinoma (HCC), due to acquired resistance. Here, we aim to identify target proteins and investigate their roles in 5-FU sensitivity of HCC cells. Methods. Mass spectrometry (MS) proteomics was performed on 5-FU-resistant cell line (BEL7402/5-FU) and its parental cell line (BEL7402) with 5-FU treatment. In order to identify potential targets, we compared the proteomics between two cell line groups and used bioinformatics tools to select hub proteins from all differentially expressed proteins. Results. We finally focused on a group of cell cycle-related kinases (CDKs). By CCK8 assay, we confirmed that the CDK inhibitor significantly decreased the IC50 of 5-FU-resistant cells. Conclusions. Our study verified that CDK inhibition can reverse 5-FU resistance of HCC cells.

引用

页数：9

共 31 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[2]

Brown VD, 1999, MOL CELL BIOL, V19, P3246

[3] miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O [J].

Chen, Binghai ;

Duan, Lujing ;

Yin, Guangming ;

Tan, Jing ;

Jiang, Xianzhen .

JOURNAL OF CHEMOTHERAPY, 2013, 25 (04) :229-238

[4] SiX1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the sternness of hepatocellular carcinoma cells [J].

Chen, Kehe ;

Wei, Haiming ;

Pan, Jinfei ;

Chen, Zhenxiang ;

Pan, Deng ;

Gao, Ting ;

Huang, Jingning ;

Huang, Min ;

Ou, Mei ;

Zhong, Wenhe .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 861

[5] Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway [J].

Chen, Xu-Zheng ;

Cao, Zhi-Yun ;

Chen, Tuan-Sheng ;

Zhang, You-Quan ;

Liu, Zhi-Zhen ;

Su, Yin-Tao ;

Liao, Lian-Ming ;

Du, Jian .

ONCOLOGY REPORTS, 2012, 28 (02) :742-748

[6] RB and cell cycle progression [J].

Giacinti, C. ;

Giordano, A. .

ONCOGENE, 2006, 25 (38) :5220-5227

[7] Characterization and Resistance Mechanisms of A 5-fluorouracil-resistant Hepatocellular Carcinoma Cell Line [J].

Gu, Wei ;

Fang, Fan-Fu ;

Li, Bai ;

Cheng, Bin-Bin ;

Ling, Chang-Quan .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) :4807-4814

[8]

JOHNSTON PG, 1995, CANCER RES, V55, P1407

[9]

Kasahara M, 2000, CLIN CANCER RES, V6, P2707

[10] Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU [J].

Li, Xin ;

Yu, Jie ;

Brock, Malcolm V. ;

Tao, Qian ;

Herman, James G. ;

Liang, Ping ;

Guo, Mingzhou .

ONCOTARGET, 2015, 6 (13) :11547-11560

← 1 2 3 4 →